Company Profile: Research & Development Council of New Jersey (RDNJ)

Background

Overview

The Research & Development Council of New Jersey (RDNJ) is a non-profit organization established in 1962 to advance research and development throughout New Jersey. The Council serves as a collaborative platform for industry leaders, academic institutions, and government entities, aiming to strengthen the state's innovation ecosystem.

Mission and Vision

• Mission: To foster collaboration among industry, academia, and government to grow and strengthen STEM in education, innovation, and the economy.

• Vision: Growing STEM. Advancing innovation. Impacting the world.

Primary Area of Focus

RDNJ focuses on promoting STEM education, advocating for research-driven companies and universities, and facilitating collaboration among industry, academia, and government to drive innovation in New Jersey.

Industry Significance

As a leading organization in New Jersey's innovation landscape, RDNJ plays a pivotal role in supporting the state's research and development initiatives, thereby contributing to economic growth and technological advancement.

Key Strategic Focus

Core Objectives

• Advocate for policies that support research and development.

• Enhance STEM education and workforce development.

• Facilitate partnerships among industry, academia, and government.

Specific Areas of Specialization

• STEM education and workforce development.

• Research and development policy advocacy.

• Innovation ecosystem facilitation.

Key Technologies Utilized

RDNJ leverages various technologies to support its initiatives, including digital platforms for collaboration, data analytics tools for research, and communication technologies to engage stakeholders.

Primary Markets or Conditions Targeted

The Council primarily targets the New Jersey market, focusing on enhancing the state's research and development capabilities and fostering a robust innovation ecosystem.

Financials and Funding

Funding History

As a non-profit organization, RDNJ's funding primarily comes from membership dues, grants, and donations. Specific financial details are not publicly disclosed.

Total Funds Raised

Detailed figures regarding total funds raised are not publicly available.

Notable Investors

RDNJ's funding sources include member organizations from various sectors, including industry leaders, academic institutions, and government agencies.

Intended Utilization of Capital

The funds are utilized to support RDNJ's initiatives, including organizing events, conducting research, and facilitating programs that promote STEM education and innovation in New Jersey.

Pipeline Development

Key Pipeline Candidates

RDNJ does not develop products or services; instead, it focuses on facilitating and supporting research and development initiatives within New Jersey.

Stages of Clinical Trials or Product Development

As a non-profit organization, RDNJ does not engage in clinical trials or product development.

Target Conditions

RDNJ's initiatives aim to address challenges in STEM education, research and development policy, and innovation ecosystem development.

Relevant Timelines for Anticipated Milestones

RDNJ organizes annual events such as the Edison Patent Awards to recognize and celebrate innovations in New Jersey.

Technological Platform and Innovation

Proprietary Technologies

RDNJ does not own proprietary technologies but supports the development and commercialization of innovations within New Jersey.

Significant Scientific Methods

The Council employs various scientific methods, including data analysis, policy research, and collaborative frameworks, to support its initiatives.

AI-Driven Capabilities

While RDNJ does not develop AI technologies, it supports and promotes AI-driven innovations within New Jersey's research and development community.

Leadership Team

Executive Committee

• Virginie Maillard – Chairwoman, Head of Global Research in Simulation and Digital Twin and Head of Research in the U.S. for Siemens Foundational Technologies.

• Ian Davies, Ph.D. – Vice Chair, Principal, Princeton Catalysis Initiative.

• Dan Rosenthal – Secretary, Vice President, Product Development for the Joint Replacement Business, Stryker.

• Jeffrey Stokes – Treasurer, Senior Director-Development, PSEG.

Board Members

The Board comprises leaders from various sectors, including academia, industry, and government, such as:

• The Hon. Robert Asaro-Angelo – Commissioner, New Jersey Department of Labor & Workforce Development.

• Aaron Balog, Ph.D. – Scientific Senior Director, Protein Homeostasis & Peptide Chemistry, Bristol Myers Squibb.

• Haskell Berman – Director of External Affairs, Coriell Institute for Medical Research.

• Keith Bostian, Ph.D. – Dean of NJCSTM / Technology Transfer Office, Founder & CEO, Institute for Life Science Entrepreneurship, Kean University.

• Stefanie Brachfeld, Ph.D. – Vice Provost for Research, Montclair State University.

• Rubi Burlage, Ph.D. – Associate Vice President, Sterile Product and Device Development, Merck.

• Jeffrey Cartmell, Ph.D. – Senior Director, Intellectual Property & Grants, MTF Biologics.

• Mario M. Casabona – Founder and CEO, Casabona Ventures LLC.

• Nandu Deorkar, Ph.D. – Vice President, Research & Development, Avantor Performance Materials.

• Atam P. Dhawan, Ph.D. – Senior Vice Provost for Research, Distinguished Professor of Electrical and Computer Engineering, New Jersey Institute of Technology.

• Deborah Perez Fernandez, Ph.D. – Executive Director, Technology Transfer, Rutgers, The State University of New Jersey.

• Donald Geiss – Chief (A), Business Interface Office, U.S. Army DEVCOM Armaments Center.

• Paul Hoffman – President & CEO, Liberty Science Center.

• Louis Lombardo, Ph.D. – Global Head Discovery Chemistry, Johnson & Johnson Innovative Medicine.

• Alan J. Main, Ph.D. – Executive Vice President, Pharmaceutical Research, Lexicon Pharmaceuticals.

• Susan Miller, Ph.D. – Program Manager, Bell Labs Core Research, Nokia Bell Labs.

• William Penders – Managing Director-Sector Development, New Jersey Economic Development Authority.

• Sandra Powell-Elliott – Vice President, Life Science and Innovation, Hackensack Meridian Health.

• Aaron Price – CEO, TechUnited, New Jersey.

• Kathleen Scotto, Ph.D. – Vice Chancellor for Research, Rutgers Biomedical and Health Sciences, Rutgers, The State University of New Jersey.

• Judith Sheft – Executive Director, New Jersey Commission on Science, Innovation, and Technology.

• Stephen Socolof – Managing Partner, Tech Council Ventures.

• Ed Synakowski, Ph.D. – Vice Provost for Research and Innovation, Stevens Institute of Technology.

• Sujata Vaidyanathan, Ph.D. – Development Head, In-Market Brands and Global Health, Novartis.

• Mei Wei, Ph.D. – Vice President for Research, Rowan University.

• David Zimmerman, Ph.D., J.D. – Strategic Partnership Officer, Princeton Plasma Physics Laboratory.

Competitor Profile

Market Insights and Dynamics

RDNJ operates in a collaborative environment with various organizations aiming to enhance research and development in New Jersey. Its primary focus is on fostering collaboration rather than direct competition.

Competitor Analysis

While RDNJ collaborates with numerous organizations, it does not have direct competitors. Instead, it works alongside entities such as the New Jersey Economic Development Authority and TechUnited to promote innovation and economic development in the state.

Strategic Collaborations and Partnerships

RDNJ has established partnerships with various organizations, including:

• New Jersey Economic Development Authority (NJEDA): Collaborates on initiatives to support economic growth and innovation in New Jersey.

• TechUnited: Partners to foster technology and innovation within the state.

• Rutgers, The State University of New Jersey: Engages in joint programs to advance research and development.

Operational Insights

RDNJ's collaborative approach allows it to leverage the strengths of various organizations, enhancing its capacity to drive innovation and development in New Jersey.